Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

reckitt benckiser healthcare (uk) limited - sodium alginate, sodium bicarbonate, calcium carbonate - tablets chewable with peppermint flavor - 250mg+133.5mg+80mg

Filipinas - inglês - FDA (Food And Drug Administration)

reckitt benckiser healthcare (philippines) inc. - sodium alginate / sodium bicarbonate / calcium carbonate - chewable tablet - 250mg / 133.5mg / 80mg

Quênia - inglês - Pharmacy and Poisons Board

pine healthcare limited pine healthcare limited - sodium bicarbonate, sodium alginate and calcium… - concentrate for oral suspension - sodium bicarbonate 133.5mg/5ml, sodium alginate… - antacids with sodium bicarbonate

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - potassium hydrogen carbonate; sodium alginate - oral suspension - 500mg/ 5 ml+100 mg/5ml - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - potassium bicarbonate; sodium alginate - chewable tablet - 500/100 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Malta - inglês - Medicines Authority

charles de giorgio limited triq il-kanonku, karmenu pirotta, birkirkara bkr 1114, malta - sodium alginate, potassium bicarbonate - chewable tablet - sodium alginate 500 mg potassium bicarbonate 100 mg - drugs for acid related disorders

Estados Unidos - inglês - NLM (National Library of Medicine)

atlantic biologicals corps - sevelamer carbonate (unii: 9ycx42i8iu) (sevelamer - unii:941n5duu5c) - sevelamer carbonate 800 mg - renvela® (sevelamer carbonate) is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (ckd) on dialysis. renvela is contraindicated in patients with bowel obstruction. renvela is contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride or to any of the excipients. risk summary sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [see clinical pharmacology (12.2)] . consider supplementation. data animal data in pregnant rats given dietary doses of 0.5, 1.5 or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin d, occurred in mid- and high-dose groups (hu

Malta - inglês - Medicines Authority

charles de giorgio limited triq il-kanonku, karmenu pirotta, birkirkara bkr 1114, malta - sodium alginate, sodium hydrogen, carbonate, calcium carbonate - chewable tablet - sodium alginate 250 mg sodium hydrogen carbonate 133.5 mg calcium carbonate 80 mg - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Estados Unidos - inglês - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate extended-release tablets is indicated in the treatment of manic episodes of manic-depressive illness. maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania.  typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. when given to a patient experiencing a manic episode, lithium carbonate extended-release tablets may produce a normalization of symptomatology within 1 to 3 weeks.

Estados Unidos - inglês - NLM (National Library of Medicine)

remedyrepack inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate extended-release tablets are indicated in the treatment of manic episodes of manic-depressive illness. maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. when given to a patient experiencing a manic episode, lithium carbonate extended-release tablets may produce a normalization of symptomatology within 1 to 3 weeks.